MX2011013113A - Soluciones de inyeccion e infusion de diacetato de ipamorelin. - Google Patents

Soluciones de inyeccion e infusion de diacetato de ipamorelin.

Info

Publication number
MX2011013113A
MX2011013113A MX2011013113A MX2011013113A MX2011013113A MX 2011013113 A MX2011013113 A MX 2011013113A MX 2011013113 A MX2011013113 A MX 2011013113A MX 2011013113 A MX2011013113 A MX 2011013113A MX 2011013113 A MX2011013113 A MX 2011013113A
Authority
MX
Mexico
Prior art keywords
ipamorelin
injection
infusion solutions
diacetate
acetic acid
Prior art date
Application number
MX2011013113A
Other languages
English (en)
Inventor
Riccardo Braglia
Silvina Garcia Rubio
Daniel Beidler
Helle Weibel
Original Assignee
Helsinn Therapeutics Us Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42272260&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2011013113(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Helsinn Therapeutics Us Inc filed Critical Helsinn Therapeutics Us Inc
Publication of MX2011013113A publication Critical patent/MX2011013113A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

Las soluciones de inyección o difusión de ipamorelin, que tiene la siguiente composición: a) ipamorelin solubilizada por aproximadamente dos equivalentes molares de ácido acético (diacetato de ipamorelin), en una cantidad desde 0.001 a 20%, basado en el peso de la base libre de ipamorelin; b) un exceso molar de ácido, preferentemente ácido acético, en una cantidad suficiente para dar un pH de al menos 3 y menor que 7; c) opcionalmente de 0.1 a 30% de uno o más auxiliares de formulación; y d) agua en cantidad suficiente para completar el 100%; todos los porcentajes basados en el peso total de la solución.
MX2011013113A 2009-06-12 2010-05-27 Soluciones de inyeccion e infusion de diacetato de ipamorelin. MX2011013113A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18659509P 2009-06-12 2009-06-12
PCT/US2010/036365 WO2010144265A2 (en) 2009-06-12 2010-05-27 Ipamorelin diacetate injection and infusion solutions

Publications (1)

Publication Number Publication Date
MX2011013113A true MX2011013113A (es) 2012-02-21

Family

ID=42272260

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011013113A MX2011013113A (es) 2009-06-12 2010-05-27 Soluciones de inyeccion e infusion de diacetato de ipamorelin.

Country Status (24)

Country Link
US (1) US20100317581A1 (es)
EP (1) EP2440180B1 (es)
JP (1) JP2012529510A (es)
KR (1) KR20120030530A (es)
CN (1) CN102481251A (es)
AU (1) AU2010259102B2 (es)
BR (1) BRPI1012931A2 (es)
CA (1) CA2765233A1 (es)
CL (1) CL2011003131A1 (es)
CO (1) CO6470880A2 (es)
CR (1) CR20110618A (es)
CU (1) CU20110232A7 (es)
DO (1) DOP2011000383A (es)
EA (1) EA201270011A1 (es)
EC (1) ECSP11011516A (es)
GT (1) GT201100318A (es)
MX (1) MX2011013113A (es)
NI (1) NI201100212A (es)
NZ (1) NZ596641A (es)
PE (1) PE20121064A1 (es)
SG (1) SG176717A1 (es)
TW (1) TW201106961A (es)
UA (1) UA104762C2 (es)
WO (1) WO2010144265A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6193017B2 (ja) * 2013-06-28 2017-09-06 テルモ株式会社 生体血管内血液置換用液体、生体血管内血液置換用液体製剤およびプレフィルドシリンジ
JP6562902B2 (ja) 2014-03-28 2019-08-21 テルモ株式会社 生体血管内血液置換用液体、生体血管内血液置換用液体製剤およびプレフィルドシリンジ

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL112112A (en) * 1993-12-23 2000-06-29 Novo Nordisk As Peptides with growth hormone releasing properties and pharmaceutical compositions containing them
AU4911500A (en) * 1999-06-04 2000-12-28 Novo Nordisk A/S Compositions for the treatment of the catabolic state of prolonged critical illness
US8263551B2 (en) * 2004-11-22 2012-09-11 Novo Nordisk A/S Soluble, stable insulin-containing formulations with a protamine salt
KR100700869B1 (ko) * 2005-06-03 2007-03-29 재단법인 목암생명공학연구소 Ｐｔｈ, 완충제 및 안정제를 포함하는 안정한 ｐｔｈ조성물
ES2748526T3 (es) * 2006-12-21 2020-03-17 Amgen Inc Formulaciones tamponadas estables que contienen polipéptidos
TWI429436B (zh) * 2007-04-10 2014-03-11 Helsinn Therapeutics Us Inc 使用生長激素促泌素治療或預防嘔吐之方法
WO2009082426A1 (en) * 2007-12-21 2009-07-02 Helsinn Therapeutics (U.S.), Inc. Method of stimulating the motility of the gastrointestinal system using ipamorelin
UA105657C2 (uk) * 2009-02-27 2014-06-10 Хелсінн Терапьютікс (Ю.Ес.), Інк. Поліпшені способи лікування мігрені на основі анамореліну

Also Published As

Publication number Publication date
GT201100318A (es) 2014-10-13
CL2011003131A1 (es) 2012-08-17
CR20110618A (es) 2012-03-02
EP2440180B1 (en) 2014-08-27
WO2010144265A3 (en) 2011-11-24
NI201100212A (es) 2012-04-11
ECSP11011516A (es) 2012-03-30
CA2765233A1 (en) 2010-12-16
JP2012529510A (ja) 2012-11-22
AU2010259102B2 (en) 2013-09-12
KR20120030530A (ko) 2012-03-28
AU2010259102A1 (en) 2012-01-12
BRPI1012931A2 (pt) 2018-01-30
WO2010144265A2 (en) 2010-12-16
CN102481251A (zh) 2012-05-30
NZ596641A (en) 2013-12-20
US20100317581A1 (en) 2010-12-16
CU20110232A7 (es) 2012-06-21
PE20121064A1 (es) 2012-09-03
UA104762C2 (ru) 2014-03-11
DOP2011000383A (es) 2012-05-31
CO6470880A2 (es) 2012-06-29
TW201106961A (en) 2011-03-01
EA201270011A1 (ru) 2012-05-30
EP2440180A2 (en) 2012-04-18
SG176717A1 (en) 2012-01-30

Similar Documents

Publication Publication Date Title
MX349383B (es) Formulaciones para el tratamiento de diabetes.
UA105229C2 (uk) Фармацевтичний склад
PH12014501213A1 (en) Aqueous oral care compositions
NZ622566A (en) Chromobacterium bioactive compositions and metabolites
WO2008089268A3 (en) Methods and compositions for treating conditions associated with infection and/or inflammation
UA108105C2 (ru) Азотсодержащие гетероарильные соединения
MX342684B (es) Regimen de dosificacion escalante para efectuar la perdida de peso y el tratamiento de obesidad.
IN2012DN00765A (es)
WO2009117150A3 (en) Method of treating lupus with ceramide derivatives
UA103373C2 (ru) Стабильное соединение феррума олигосахарида
UA102858C2 (ru) Производные пиридино-пиридинонов, способ их получения и применения в терапии
MX2013012151A (es) Metodo para inhibir microorganismos dañinos y composicion de formacion de barreras para los mismos.
MX2011013648A (es) Nuevos compuestos, composiciones farmaceuticas y metodos relacionados con ellos.
MX359318B (es) Composiciones que comprenden polietilenglicol y ascorbato.
NZ614434A (en) High-strength, low viscosity herbicidal concentrate of clopyralid dimethylamine
MX2011007543A (es) Compuesto ciclico que contiene heteroatomos.
IN2012DN05192A (es)
WO2009051217A1 (ja) フェンタニル含有経皮吸収製剤
WO2007133796A3 (en) Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
NZ593715A (en) N-alkoxycarboxamides for controlling infestation of plants by microorganisms such as fungi
MX2010009577A (es) Derivados de piridopirazinona que estimulan la secrecion de insulina, metodos para obtenerlos y su uso en el tratamiento de la diabetes.
MX2010010345A (es) Composiciones oftalmicas topicas mejoradas.
UA104762C2 (ru) Раствор для инъекции или инфузии ипаморелина диацетата
MX2010003594A (es) Formas cristalinas de sal sodica de dmxaa.
MX2012001107A (es) Derivado de amida.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal